3 not yet recruiting. 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Carbapenem-resistant Enterobacterales: new trials by email Literature Review of Carbapenem-resistant Enterobacterales trials Research Report on Carbapenem-resistant Enterobacterales
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation Ceftazidime - Avibactam ( CAZ-AVI), Meropenem-Vaborbactam, Imipenem+Relebactam - Liver Transplant, Carbapenem-resistant Enterobacterales | Phase 3 | Not yet recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 168 | 2026-10-01 | 2026-08-12 |
| Perianal MBL-CRE Colonization and Infection in Allogeneic Hematopoietic Stem Cell Transplant Patients ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Carbapenem-resistant Enterobacterales | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 1000 | 2026-01-01 | 2026-01-07 | |
| Prospective Study Evaluate the Timing of Empirical Treatment for Carbapenem-resistant Bacterials (CROEAT Study) Empirical treatment - Carbapenem-resistant Enterobacterales, Neutropenia | Not applicable | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 91 | 2025-08-01 | 2025-07-02 |
Hematologic Neoplasms (1) · Neutropenia (1)
Agranulocytosis (1) · Cytopenia (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Leukocyte Disorders (1) · Leukopenia (1) · Neoplasms (1) · Neoplasms by Site (1)
Amoxicillin-Potassium Clavulanate Combination (1) · Aztreonam (1) · Cefiderocol (1) · Piperacillin, Tazobactam Drug Combination (1) · Tigecycline (1) · avibactam, ceftazidime drug combination (1) · eravacycline (1) · imipenem, cilastatin and relebactam (1) · meropenem and vaborbactam (1)
IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Shanghai Jiao Tong University School of Medicine (1)
China (1) · Italy (1)
Jiong Hu (1) · Maddalena Giannella, MD, PhD (1)
2025 (1)